{"id":1352,"date":"2026-03-23T06:29:12","date_gmt":"2026-03-23T06:29:12","guid":{"rendered":"https:\/\/kishiwada.tokushukai.or.jp\/en\/departments\/neurology\/leqembi\/"},"modified":"2026-04-11T03:56:14","modified_gmt":"2026-04-11T03:56:14","slug":"leqembi","status":"publish","type":"page","link":"https:\/\/kishiwada.tokushukai.or.jp\/en\/departments\/neurology\/leqembi\/","title":{"rendered":"Lecanemab (Leqembi\u00ae) \u2014 Eligibility & Treatment Planning"},"content":{"rendered":"
\n
\n
\n
\n
What we do<\/div>\n
Assessment and treatment planning for disease-modifying therapies in Alzheimer’s disease<\/div>\n<\/p><\/div>\n
\n
Purpose<\/div>\n
Confirm eligibility and plan safe treatment and monitoring<\/div>\n<\/p><\/div>\n
\n
Urgent care<\/div>\n
Immediate evaluation if new neurological symptoms develop during treatment<\/div>\n<\/p><\/div>\n<\/p><\/div>\n

\n Lecanemab (Leqembi\u00ae) and Donanemab (Kisunla\u00ae) are treatment options for selected patients with
\n early Alzheimer’s disease<\/strong> or mild cognitive impairment (MCI) due to Alzheimer’s disease<\/strong>.
\n We assess whether these treatments are appropriate and explain the expected course, risks, and monitoring requirements.\n <\/p>\n<\/header>\n

\n
\n
\n

About these treatments<\/h2>\n<\/p><\/div>\n
\n
\n

Lecanemab (Leqembi\u00ae)<\/strong><\/p>\n

    \n
  • Intravenous infusion every two weeks<\/strong><\/li>\n
  • Targets amyloid plaques in the brain<\/li>\n
  • Used in early Alzheimer’s disease and MCI due to Alzheimer’s disease<\/li>\n<\/ul><\/div>\n
    \n

    Donanemab (Kisunla\u00ae)<\/strong><\/p>\n

      \n
    • Intravenous infusion once per month<\/strong><\/li>\n
    • Also targets amyloid plaques<\/li>\n
    • Treatment duration may vary depending on response<\/li>\n<\/ul><\/div>\n

      \n Both treatments require regular hospital visits for infusion and monitoring.
      \n This should be considered in advance, particularly for patients travelling from overseas.\n <\/p>\n<\/p><\/div>\n<\/p><\/div>\n

      \n
      \n

      Who may be considered<\/h2>\n<\/p><\/div>\n
      \n
      \n
        \n
      • Early-stage symptoms consistent with Alzheimer’s disease<\/li>\n
      • MCI due to Alzheimer’s disease or mild Alzheimer’s dementia<\/li>\n
      • Evidence of amyloid pathology (e.g., amyloid PET or equivalent)<\/li>\n
      • Able to attend scheduled infusion and monitoring visits<\/li>\n
      • Support from a caregiver or family member is recommended<\/li>\n<\/ul><\/div>\n

        \n Eligibility is determined individually. These treatments are not suitable for all patients with memory symptoms.\n <\/p>\n<\/p><\/div>\n<\/p><\/div>\n

        \n
        \n

        Monitoring and safety<\/h2>\n<\/p><\/div>\n
        \n

        \n Treatment requires regular monitoring.
        \n One important consideration is ARIA<\/strong> (amyloid-related imaging abnormalities),
        \n which is assessed using MRI.\n <\/p>\n

        \n